Drs. Eric Rowinsky and James Tonra: A New Phase 1/​1B Study of ST-01156, a Small Molecule RBM39 Protein Degrader

Ewing's U
Written By Alana Arens

Drs. Eric Rowinsky and James Tonra of Seed Therapeutics present on recently opened clinical trial (NCT07197554) for solid tumor, with specific focus on Ewing sarcoma. ST-01165 is a orally administered, protein degrader (molecular glue), targeting RMB39 - a key regulator of RNA splicing and transcription required for tumor cell proliferation.

Alana Arens
Next

GRANT: LWF Doubles Down on Partnership with Aptadel Therapeutics (Barcelona, Spain)